Cell Pathways (CLPA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Pathways (CLPA)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (329)	11/1/1999 12:02:00 PM
From: Neuroguy	Read Replies (1) of 566

tuck - nice analysis It's true that the FDA could surprise and review Aptosyn prior to the ODAC meeting, but seems unlikely IMO. One really never knows though. Between now and then the shorts will be trying to ease themselves out to avoid being caught in a massive squeeze. In the next 6 weeks we have both ODAC and the postate PIII results to look forward to. If the final prostate data is as promising as the interim analysis suggested, it could in itself attract some major media coverage. As for IMCL, I hold that also, but frankly as a medical researcher by trade, I have less enthusiasm for the science there. I am not unenthusiastic though, just not AS enthusiastic! Trav

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next